PLX

Protalix Biotherapeutics Stock Analysis

AI Rating

Great
  • Quality6/10
  • Growth↑ 9/10
  • Momentum↑ 9/10
Protalix Biotherapeutics sales and earnings growth
PLX Growth
Great
  • Revenue Y/Y↑ 35.42%
  • EPS Y/Y↑ 146.67%
  • FCF Y/Y↓ -262.98%
Protalix Biotherapeutics gross and profit margin trends
PLX Profitability
Great
  • Gross margin ↑ 57.50%
  • EPS margin↓ 8.70%
  • ROIC↑ 18.00%
Protalix Biotherapeutics net debt vs free cash flow
PLX Risk
Great
  • Debt / Equity↓ 0.2
  • Debt / FCF↓ 0.0
  • Interest coverage↑ 7.7

Protalix Biotherapeutics stock is less volatile than the overall market, so it's low risk. We give it a Great risk rating.

More Biotechnology stocks ↗